drugset
drugset / Trial / NCT01337518

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

NCT01337518 ↗

Phase 1 Suspended 150 enrolled Enzon Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC). Goals of this phase I study include finding out the dose of EZN-4176 that can be safely given without serious side effects and to determine the amount of EZN-4176 that should be given in future studies.

Timeline

Start
2011-03
Primary completion
2013-12
Completion
2013-12

Outcome

Outcome not reported

Stopped (Business): “Reassessment of strategic direction”

Drugs

EvaluationDrugModalityDoseRoute
Subject EZN-4176 Unknown — Intravenous

Indications

prostate neoplasm